Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Endava plc - ADR

DocuSign

NiSource

Root

Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).

Bet on 5 Top Stocks With Rising P/E

Novartis

Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.

Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

Clovis Oncology (NASDAQ: CLVS ) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. The first thing that investors need to know about is Clovis Oncology's plan for this bankruptcy.

CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy

Clovis Oncology Inc. stock CLVS, -9.94% fell 10% in premarket trade Monday, after the biotech filed for Chapter 11 bankruptcy and said it would sell assets. The company has a commitment for up to $75 million in debtor-in-possession financing to provide the liquidity needed to restructure in bankruptcy and pay its vendors and customers.

Clovis Oncology stock slides 10% premarket after company files for bankruptcy

BOULDER, Colo.--( BUSINESS WIRE )--Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the “Debtors”) have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) and will seek to sell their assets through a court supervised sales process.

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

Investors in Clovis Oncology (NASDAQ: CLVS ) stock will want to prepare for a bankruptcy filing following a warning from the pharmaceutical company. According to a filing with the U.S. Securities and Exchange Commission (SEC), the company is expecting to file for Chapter 11 bankruptcy protection.

Dear CLVS Stock Fans, Get Ready for a Bankruptcy Filing

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)

Golden Minerals Company

Intrusion

SemiLEDs

Steel Connect

Once again, I drew the short (no pun intended) end of the stick and must discuss stocks to sell right now. Understandably a sensitive topic and one that arouses myriad emotions, I'm just going to stick with the hard numbers.

7 Stocks to Sell Right Now

Core Scientific Inc

Faraday Future Intelligent Electric

Hycroft Mining Holding Corporation

OneConnect Financial Tech Co Ltd ADR

Otonomy

SINTX Technologies Inc

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 7 To Watch Under $1 Right Now

There's nothing like a good old-fashioned bankruptcy warning to make a stock pop on a given day. Today, the latest speculative frenzy appears to be underway with Clovis Oncology (NASDAQ: CLVS ).

Clovis Oncology (CLVS) Stock Pops After Bankruptcy Warning

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

Clovis Oncology (NASDAQ: CLVS ) stock is crashing on Wednesday as investors react to news of the company running out of cash! According to a recent filing from Clovis Oncology, there's a strong chance it files for bankruptcy in the near future.

Why Is Clovis Oncology (CLVS) Stock Down 72% Today?

Clovis Oncology Inc. shares CLVS, -73.37% plunged 75% Wednesday, after the Colorado-based biotech said it will not have sufficient liquidity to maintain operations beyond January of 2023. The company said recent regulatory developments relating to its ovarian cancer drug Rubraca and challenges in raising fresh capital, "a potential bankruptcy filing in the very near term looks increasingly probable as a way to preserve the value of our business and assets for the benefit of our stakeholders.

Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023

Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates

U.S. drugmaker Clovis Oncology said on Wednesday it was likely to file for bankruptcy "in the very near term", as the company struggles to sell its cancer drug Rubraca.

Cancer drugmaker Clovis flags possible bankruptcy

Clovis Oncology continues to report positive clinical data from Rubraca and FAP-2286. I believe these updates make Clovis a prime acquisition target. I review some of the company's recent updates.

Clovis Oncology: Looking Like An Acquisition Target After Recent Company Updates

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

In a still-fresh press release, Clovis Oncology (NASDAQ: CLVS ) just announced that its Phase 3 trial for Rubraca, a prostate cancer treatment, achieved its primary endpoint. Moreover, Clovis plans to submit a supplemental New Drug Application (NDA) to the Food and Drug Administration (FDA) for a specific subgroup of prostate cancer patients and intends to discuss NDA submission for a broader patient population with the FDA.

Why Is Clovis Oncology (CLVS) Stock Up Today?

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca monotherapy treatment achieved the primary endpoint of significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR) compared with the control group, which consisted of physician's choice of docetaxel, abiraterone acetate, or enzalutamide. Benefit wa

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

Source: rafapress / Shutterstock.com Clovis Oncology (NASDAQ: CLVS ) stock is getting a boost on Wednesday as investors react to news of it reaching a two-year clinical supply agreement. That agreement was signed with Isotopia Molecular Imaging and it supplies Clovis Oncology with lutetium-177.

What Is Going on With Clovis Oncology (CLVS) Stock Today?

BOULDER, Colo. & PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CLVS--Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

News for Clovis Oncology Stock (CLVS)